Limbix, a San Francisco CA-based prescription digital therapeutic company, raised d$15M in Series A2 funding.
The round, which brings total funding to date to $31m, was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink, DN Capital, Korean Investment Partners, E& Investment, Gaingels, MVP, Operator Partners, Mana Ventures and Pacific Health Ventures.
The company intends to use the funds to expand its commercialization efforts and to double its staff to approximately 60 employees by Q2, 2022.
Led by Ben Lewis, CEO, Limbix is a prescription digital therapeutic company creating mental health treatments for adolescents via a team of clinicians, product designers, researchers, and engineers. Last month, Limbix launched SparkRx, a digital therapeutic for adolescents with symptoms of depression.
The program is based on core principles of cognitive behavioral therapy with a focus on behavioral activation and is delivered to patients via smartphone. Limbix also recently announced positive results from a clinical trial of SparkRx, which demonstrated a statistically significant reduction in depression symptoms, compared to an active control, for users who completed the program as recommended.